First-line enfortumab vedotin-pembrolizumab versus nivolumab plus gemcitabine-cisplatin in metastatic urothelial cancer: a cost-effectiveness study

Under current pricing and reimbursement assumptions, N + GC is economically preferable to EV + P as a first-line strategy for la/mUC in both the US and China. EV + P may warrant consideration only in tightly selected scenarios or with substantial coordinated price reductions and policy changes. Meanwhile, it should be noted that due to the inherent limitations of the indirect comparison method between drugs, the conclusions of this study should be regarded as exploratory analysis results.